The Valley Desk

NCT04776252 · Interventional trial

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

Overall registry status Active not recruiting

Phase 3

Conditions HIV-1 Infection

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov